Human study · Supplements / medicine · 26 Sept 2026
Walking pain in the leg can be peripheral artery disease, and a Canadian plan says it is still found too late
Source: The Conversation / Canadian Journal of Cardiology
What the research found
Commentary (clinical action plan). Matthew Ades, Anthony Sandre, Sonia S. Anand, and colleagues, writing in the Canadian Journal of Cardiology (doi 10.1016/j.cjca.2026.03.010; Medical Xpress 26 September 2026), describe peripheral artery disease as plaque that narrows arteries, most often those to the legs. It is the same process behind many heart attacks and strokes. A common symptom is aching, cramping, or fatigue in the leg muscles while walking that eases with rest, called claudication. Symptoms are not always typical, and some people have few or none, so they may simply walk less and treat it as aging or arthritis. The Canadian National Action Plan for Peripheral Artery Disease, from the Canadian Society of Vascular Medicine and the Canadian Society of Vascular Surgery, names six areas: awareness, earlier diagnosis, treatment pathways, Indigenous-led care, research, and advocacy. It cites an estimate that Canadian medical students may get about 15 minutes of teaching specific to this disease. A simple check is the ankle-brachial index, blood pressure at the ankle compared with the arm. The authors say much of the harm is preventable once the disease is recognized: stopping smoking, managing blood pressure, cholesterol, and diabetes, appropriate medicines, and regular walking exercise. Procedures to restore flow are for more advanced disease. Smoking and diabetes carry the highest risk, and the burden is heavier where preventive care is harder to reach. This is a care plan, not a trial of a walking program. Educational notes. Leg pain with walking belongs with a clinician.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
Read the original at The Conversation / Canadian Journal of Cardiology
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34